The aim of this study is to assess the safety and efficacy of varying doses of ISIS 301012 (mipomersen) as add-on therapy in subjects with Heterozygous Familial Hypercholesterolemia
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
44
50 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
100 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
200 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
Unnamed facility
Chicago, Illinois, United States
Unnamed facility
Auburn, Maine, United States
Unnamed facility
Scarborough, Maine, United States
Unnamed facility
New York, New York, United States
Percent reduction in LDL-cholesterol from baseline
Time frame: Week 7 (Cohorts A-C), Week 15 (Cohort D)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
300 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
Unnamed facility
Winston-Salem, North Carolina, United States
Unnamed facility
Cincinnati, Ohio, United States
Unnamed facility
Houston, Texas, United States
Unnamed facility
Amsterdam, Netherlands